The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Mark John Millan

Institut de Recherches Servier

Centre de Recherches de Croissy

Psychopharmacology Department

125 Chemin de Ronde



Name/email consistency: high



  • Institut de Recherches Servier, Centre de Recherches de Croissy, Psychopharmacology Department, 125 Chemin de Ronde, France. 2012
  • IDR Servier, 125 chemin de Ronde, 78290 Croissy/Seine, Paris, France. 2011
  • Dept of Psychopharmacology, Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy/Seine (Paris), France. 2000 - 2010
  • Institut de Recherches Servier, Croissy sur Seine, France. 2008 - 2010


  1. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. Millan, M.J., Mannoury la Cour, C., Chanrion, B., Dupuis, D.S., Di Cara, B., Audinot, V., Cussac, D., Newman-Tancredi, A., Kamal, M., Boutin, J.A., Jockers, R., Marin, P., Bockaert, J., Muller, O., Dekeyne, A., Lavielle, G. J. Pharmacol. Exp. Ther. (2012) [Pubmed]
  2. MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues. Millan, M.J. Curr. Opin. Pharmacol (2011) [Pubmed]
  3. From the cell to the clinic: a comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Millan, M.J. Pharmacol. Ther. (2010) [Pubmed]
  4. S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine. Millan, M.J., Dekeyne, A., Gobert, A., Mannoury la Cour, C., Brocco, M., Rivet, J.M., Di Cara, B., Lejeune, F., Cremers, T.I., Flik, G., de Jong, T.R., Olivier, B., de Nanteuil, G. Eur. Neuropsychopharmacol (2010) [Pubmed]
  5. The dopamine D(3) receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Millan, M.J., Buccafusco, J.J., Loiseau, F., Watson, D.J., Decamp, E., Fone, K.C., Thomasson-Perret, N., Hill, M., Mocaer, E., Schneider, J.S. Int. J. Neuropsychopharmacol. (2010) [Pubmed]
  6. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Millan, M.J. Neurotherapeutics (2009) [Pubmed]
  7. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Millan, M.J., Marin, P., Bockaert, J., Mannoury la Cour, C. Trends Pharmacol. Sci. (2008) [Pubmed]
  8. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. Millan, M.J., Loiseau, F., Dekeyne, A., Gobert, A., Flik, G., Cremers, T.I., Rivet, J.M., Sicard, D., Billiras, R., Brocco, M. J. Pharmacol. Exp. Ther. (2008) [Pubmed]
  9. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. Millan, M.J., Mannoury la Cour, C., Novi, F., Maggio, R., Audinot, V., Newman-Tancredi, A., Cussac, D., Pasteau, V., Boutin, J.A., Dubuffet, T., Lavielle, G. J. Pharmacol. Exp. Ther. (2008) [Pubmed]
  10. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. Millan, M.J., Svenningsson, P., Ashby, C.R., Hill, M., Egeland, M., Dekeyne, A., Brocco, M., Di Cara, B., Lejeune, F., Thomasson, N., Munoz, C., Mocaër, E., Crossman, A., Cistarelli, L., Girardon, S., Iob, L., Veiga, S., Gobert, A. J. Pharmacol. Exp. Ther. (2008) [Pubmed]
  11. The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats. Millan, M.J., Gobert, A., Panayi, F., Rivet, J.M., Dekeyne, A., Brocco, M., Ortuno, J.C., Di Cara, B. Int. J. Neuropsychopharmacol. (2008) [Pubmed]
  12. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138. Millan, M.J., Brocco, M. Therapie (2008) [Pubmed]
  13. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with alpha/beta-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors. Millan, M.J., Dekeyne, A. Int. J. Neuropsychopharmacol. (2007) [Pubmed]
  14. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors. Millan, M.J., Iob, L., Péglion, J.L., Dekeyne, A. Psychopharmacology (Berl.) (2007) [Pubmed]
  15. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. Millan, M.J., Di Cara, B., Dekeyne, A., Panayi, F., De Groote, L., Sicard, D., Cistarelli, L., Billiras, R., Gobert, A. J. Neurochem. (2007) [Pubmed]
  16. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Millan, M.J. Pharmacol. Ther. (2006) [Pubmed]
  17. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Millan, M.J., Brocco, M., Gobert, A., Dekeyne, A. Psychopharmacology (Berl.) (2005) [Pubmed]
  18. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Millan, M.J. Psychopharmacology (Berl.) (2005) [Pubmed]
  19. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Millan, M.J. Therapie (2005) [Pubmed]
  20. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole. Millan, M.J., Cussac, D., Gobert, A., Lejeune, F., Rivet, J.M., Mannoury La Cour, C., Newman-Tancredi, A., Peglion, J.L. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  21. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. Millan, M.J., Di Cara, B., Hill, M., Jackson, M., Joyce, J.N., Brotchie, J., McGuire, S., Crossman, A., Smith, L., Jenner, P., Gobert, A., Peglion, J.L., Brocco, M. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  22. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. Millan, M.J., Brocco, M., Papp, M., Serres, F., La Rochelle, C.D., Sharp, T., Peglion, J.L., Dekeyne, A. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  23. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Millan, M.J., Seguin, L., Gobert, A., Cussac, D., Brocco, M. Psychopharmacology (Berl.) (2004) [Pubmed]
  24. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis. Millan, M.J., Gobert, A., Roux, S., Porsolt, R., Meneses, A., Carli, M., Di Cara, B., Jaffard, R., Rivet, J.M., Lestage, P., Mocaer, E., Peglion, J.L., Dekeyne, A. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  25. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Millan, M.J. Eur. J. Pharmacol. (2004) [Pubmed]
  26. The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines. Millan, M.J., Brocco, M. Eur. J. Pharmacol. (2003) [Pubmed]
  27. Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes. Millan, M.J., Veiga, S., Girardon, S., Brocco, M. Psychopharmacology (Berl.) (2003) [Pubmed]
  28. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Millan, M.J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J.M., Cussac, D. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  29. The neurobiology and control of anxious states. Millan, M.J. Prog. Neurobiol. (2003) [Pubmed]
  30. Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterization. Millan, M.J., Newman-Tancredi, A., Lochon, S., Touzard, M., Aubry, S., Audinot, V. Pharmacol. Biochem. Behav. (2002) [Pubmed]
  31. Stereospecific blockade of marble-burying behaviour in mice by selective, non-peptidergic neurokinin1 (NK1) receptor antagonists. Millan, M.J., Girardon, S., Mullot, J., Brocco, M., Dekeyne, A. Neuropharmacology (2002) [Pubmed]
  32. Descending control of pain. Millan, M.J. Prog. Neurobiol. (2002) [Pubmed]
  33. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. Millan, M.J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J.A., Newman-Tancredi, A. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  34. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Millan, M.J. Curr. Drug. Targets. CNS. Neurol. Disord (2002) [Pubmed]
  35. Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. Millan, M.J., Lejeune, F., De Nanteuil, G., Gobert, A. J. Neurochem. (2001) [Pubmed]
  36. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. Millan, M.J., Cussac, D., Milligan, G., Carr, C., Audinot, V., Gobert, A., Lejeune, F., Rivet, J.M., Brocco, M., Duqueyroix, D., Nicolas, J.P., Boutin, J.A., Newman-Tancredi, A. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  37. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. Millan, M.J., Gobert, A., Lejeune, F., Newman-Tancredi, A., Rivet, J.M., Auclair, A., Peglion, J.L. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  38. S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. Millan, M.J., Dekeyne, A., Papp, M., La Rochelle, C.D., MacSweeny, C., Peglion, J.L., Brocco, M. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  39. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Millan, M.J., Brocco, M., Gobert, A., Dorey, G., Casara, P., Dekeyne, A. Neuropsychopharmacology (2001) [Pubmed]
  40. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. Millan, M.J. J. Pharmacol. Exp. Ther. (2000) [Pubmed]
WikiGenes - Universities